AstraZeneca’s blood cancer drug meets main goal in late-stage trial

(Reuters) – AstraZeneca Plc said on Thursday its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month.

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.

Calquence, which is already approved by the U.S. drug regulator to treat a rare type of blood cancer, also met the primary endpoint in a trial in May testing the drug in comparison with available treatment.


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments